Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers
Magali Noval Rivas, … , Susan Cheng, Moshe Arditi
Magali Noval Rivas, … , Susan Cheng, Moshe Arditi
Published November 19, 2020
Citation Information: J Clin Invest. 2021;131(2):e145157. https://doi.org/10.1172/JCI145157.
View: Text | PDF
Clinical Medicine COVID-19 Vaccines

BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers

  • Text
  • PDF
Abstract

BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 1 million deaths worldwide; thus, there is an urgent need to develop preventive and therapeutic strategies. The antituberculosis vaccine bacillus Calmette-Guérin (BCG) demonstrates nonspecific, protective innate immune–boosting effects. Here, we determined whether a history of BCG vaccination was associated with decreased SARS-CoV-2 infection and seroconversion in a longitudinal, retrospective observational study of a diverse cohort of health care workers (HCWs).METHODS We assessed SARS-CoV-2 seroprevalence and collected medical questionnaires, which included information on BCG vaccination status and preexisting demographic and clinical characteristics, from an observational cohort of HCWs in a multisite Los Angeles health care organization. We used multivariate analysis to determine whether a history of BCG vaccination was associated with decreased rates of SARS-CoV-2 infection and seroconversion.RESULTS Of the 6201 HCWs, 29.6% reported a history of BCG vaccination, whereas 68.9% had not received BCG vaccination. Seroprevalence of anti–SARS-CoV-2 IgG as well as the incidence of self-reported clinical symptoms associated with coronavirus disease 2019 (COVID-19) were markedly decreased among HCWs with a history of BCG vaccination compared with those without BCG vaccination. After adjusting for age and sex, we found that a history of BCG vaccination, but not meningococcal, pneumococcal, or influenza vaccination, was associated with decreased SARS-CoV-2 IgG seroconversion.CONCLUSIONS A history of BCG vaccination was associated with a decrease in the seroprevalence of anti–SARS-CoV-2 IgG and a lower number of participants who self-reported experiencing COVID-19–related clinical symptoms in this cohort of HCWs. Therefore, large randomized, prospective clinical trials of BCG vaccination are urgently needed to confirm whether BCG vaccination can confer a protective effect against SARS-CoV-2 infection.

Authors

Magali Noval Rivas, Joseph E. Ebinger, Min Wu, Nancy Sun, Jonathan Braun, Kimia Sobhani, Jennifer E. Van Eyk, Susan Cheng, Moshe Arditi

×

Figure 3

Meningococcal, Pneumovax, and influenza vaccinations are not associated with a beneficial effect of reducing COVID-19–related symptoms or SARS-CoV-2 infection.

Options: View larger image (or click on image) Download as PowerPoint
Meningococcal, Pneumovax, and influenza vaccinations are not associated ...
(A) Percentage of individuals in the entire cohort who reported a history of meningococcal (n = 1842), Pneumovax (n = 1007), or influenza (n = 6014) vaccination. (B) Percentage of individuals with a history of meningococcal, Pneumovax, or influenza vaccination who experienced COVID-19–related symptoms. (C) Percentage of individuals with or without a history of meningococcal, Pneumovax, or influenza vaccination who did not experience COVID-19–related symptoms during the prior 6 months. (D) Percentage of participants with or without a history of meningococcal, Pneumovax, or influenza vaccination who self-reported a medical diagnosis of COVID-19. (E) Percentage of participants with or without a history of meningococcal, Pneumovax, or influenza vaccination who self-reported a positive SARS-CoV-2 RT-PCR test. (F) Percentage of participants with or without a history of meningococcal, Pneumovax, or influenza vaccination with a positive anti–SARS-CoV-2 IgG test result. (G) Percentage of individuals with or without a history of meningococcal, Pneumovax, or influenza vaccination with a SARS-CoV-2 IgG index threshold of 0.4 or lower (left panel) or higher than 0.4. Significant P values (P < 0.05) by χ2 test are displayed for each plot.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts